MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-13-2026
AcelRx Pharmaceuticals DPO Ratio 2011-2026 | ACRX
Annual DPO Ratio AcelRx Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 38 | 58.9 | 67.8 | - | 236 | 166 | 92.2 | 190 | 48.8 | 46.2 | 322 | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 322 | 38 | 127 |
Quarterly DPO Ratio AcelRx Pharmaceuticals
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 40.5 | 43.4 | 32.4 | 34 | - | 39.1 | 47.8 | 63.8 | - | - | - | - | - | 353 | 266 | 281 | - | 433 | 227 | 262 | - | 135 | 182 | 135 | - | 73.1 | 86.7 | 141 | - | 216 | 252 | 143 | - | 64 | 36.7 | 33 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 433 | 32.4 | 145 |
DPO Ratio of other stocks in the Drug manufacturers industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Endo International plc
ENDP
|
39.3 | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
5.36 K | - | - | $ 36.6 M |  USA |
 |
Cumberland Pharmaceuticals
CPIX
|
889 | $ 5.6 | - | $ 83.2 M | USA |
 |
DURECT Corporation
DRRX
|
4.75 K | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
345 | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
116 | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
352 | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
309 | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
212 | $ 2.63 | -1.87 % | $ 1.01 B |  Canada |
 |
Athenex
ATNX
|
111 | - | -23.39 % | $ 1.76 M | USA |
 |
Harrow Health
HROW
|
199 | $ 38.93 | 3.43 % | $ 1.43 B | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
224 | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
41.8 | - | - | $ 11.5 B | USA |
 |
Organogenesis Holdings
ORGO
|
94 | $ 2.41 | 2.99 % | $ 305 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
75.6 | - | -39.89 % | $ 27.7 M | USA |
 |
Pacira BioSciences
PCRX
|
37.3 | $ 22.74 | -1.09 % | $ 1.05 B | USA |
 |
Canopy Growth Corporation
CGC
|
51.7 | $ 0.98 | -1.71 % | $ 105 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
32.3 | $ 1.11 | 1.83 % | $ 1.38 M | USA |
 |
Aurora Cannabis
ACB
|
-807 | $ 2.95 | -2.96 % | $ 162 M | Canada |
 |
Jupiter Wellness
JUPW
|
318 | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
36.8 | - | 1.15 % | $ 7.11 M | USA |
 |
Tilray
TLRY
|
53 | $ 5.01 | 0.6 % | $ 3.1 B | Canada |
 |
Evolus
EOLS
|
59.4 | $ 6.75 | 0.3 % | $ 435 M | USA |
 |
Emergent BioSolutions
EBS
|
65.2 | $ 8.29 | -0.36 % | $ 444 M | USA |
 |
Veru
VERU
|
251 | $ 3.13 | 4.33 % | $ 45.8 M | USA |
 |
cbdMD
YCBD
|
68.6 | $ 0.67 | -2.33 % | $ 2.7 M | USA |
 |
Assertio Holdings
ASRT
|
122 | $ 23.5 | 0.09 % | $ 150 M | USA |
 |
ProPhase Labs
PRPH
|
845 | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
274 | - | - | $ 1.42 B | USA |
 |
Bausch Health Companies
BHC
|
78.1 | $ 4.99 | -1.38 % | $ 1.85 B | Canada |
 |
PetIQ
PETQ
|
54.2 | - | 1.64 % | $ 400 M | USA |
 |
Recro Pharma
REPH
|
6.63 | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
109 | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
20.2 | $ 4.09 | -3.31 % | $ 204 M | USA |
 |
Viatris
VTRS
|
70.9 | $ 16.32 | -0.97 % | $ 19 B | USA |
 |
Zomedica Corp.
ZOM
|
64.3 | - | -0.21 % | $ 98 M | USA |
 |
Rockwell Medical
RMTI
|
15.4 | $ 0.64 | 2.74 % | $ 23 M | USA |
 |
China Pharma Holdings
CPHI
|
47.6 | $ 0.75 | 2.35 % | $ 3.22 M |  China |
 |
TherapeuticsMD
TXMD
|
723 | $ 2.28 | 3.64 % | $ 26.4 M | USA |